Open Access

Claudin‑1 silencing increases sensitivity of liver cancer HepG2 cells to 5‑fluorouracil by inhibiting autophagy

  • Authors:
    • Hui Tong
    • Tao Li
    • Weihua Qiu
    • Zhecheng Zhu
  • View Affiliations

  • Published online on: October 8, 2019     https://doi.org/10.3892/ol.2019.10967
  • Pages: 5709-5716
  • Copyright: © Tong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liver cancer is one of the most common cancer types globally. However, the acquisition of drug resistance limits the effectiveness of chemotherapy and commonly results in metastasis. Therefore, an effective therapeutic approach to target chemoresistance‑associated cellular molecules is imperative. Claudin‑1 (CLDN1) has previously been reported to be associated with the development of drug resistance. The present study investigated the effect of CLDN1 on the sensitivity of 5‑fluorouracil (5‑FU)‑resistant liver cancer cells. Firstly, a 5‑FU‑resistant HepG2 liver cancer cell line (Hep/5FU) was developed by continuous 5‑FU treatment. MTT proliferation, Transwell and Matrigel assays indicated that Hep/5FU cells were significantly resistant to 5‑FU, and demonstrated increased migration and invasion abilities, compared with parental HepG2 cells. Furthermore, reverse transcription‑quantitative polymerase chain reaction and western blot analysis indicated that mRNA and protein expression levels of CLDN1 were significantly increased in Hep/5FU cells, compared with HepG2 cells. CLDN1 was knocked down by transfection with small interference RNA. MTT and Annexin V‑fluorescein isothiocyanate/propidium iodide assays demonstrated that CLDN1 silencing significantly inhibits proliferation and enhances apoptosis induced by 5‑FU treatment in Hep/5FU cells, compared with non‑silenced Hep/5FU cells. Additionally, CLDN1 silencing attenuated the migration and invasion capabilities of Hep/5FU cells. In addition, it was identified that CLDN1 silencing decreased drug resistance by inhibiting autophagy, which was associated with a decrease in the ratio of microtubule‑associated protein 1A/1B‑light chain 3 (LC3)‑II/LC3‑I and upregulation of P62. A cell proliferation assay revealed that the addition of autophagy inhibitor 3‑methyladenine decreased drug resistance of Hep/5FU cells. By contrast, incubation with the autophagy agonist Rapamycin elevated drug resistance of CLDN1‑silenced Hep/5FU cells. In summary, these data indicate that CLDN1 may be a potential target for resensitizing resistant liver cancer HepG2 cells to 5‑FU by regulating cell autophagy.

Related Articles

Journal Cover

December 2019
Volume 18 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tong, H., Li, T., Qiu, W., & Zhu, Z. (2019). Claudin‑1 silencing increases sensitivity of liver cancer HepG2 cells to 5‑fluorouracil by inhibiting autophagy. Oncology Letters, 18, 5709-5716. https://doi.org/10.3892/ol.2019.10967
MLA
Tong, H., Li, T., Qiu, W., Zhu, Z."Claudin‑1 silencing increases sensitivity of liver cancer HepG2 cells to 5‑fluorouracil by inhibiting autophagy". Oncology Letters 18.6 (2019): 5709-5716.
Chicago
Tong, H., Li, T., Qiu, W., Zhu, Z."Claudin‑1 silencing increases sensitivity of liver cancer HepG2 cells to 5‑fluorouracil by inhibiting autophagy". Oncology Letters 18, no. 6 (2019): 5709-5716. https://doi.org/10.3892/ol.2019.10967